| ACPA | Anti-Citrullinated Peptide Antibody |
| ACS | Acute Coronary Syndrome |
| AD | Alzheimer’s Disease |
| ADNI | Alzheimer’s Disease Neuroimaging Initiative |
| Aβ | Beta-Amyloid (Amyloid-beta) |
| Aβ42 | Amyloid-beta 1–42 |
| Abeta40 | Amyloid-beta 1–40 |
| Anti-CCP | Anti-Cyclic Citrullinated Peptide |
| Anti-Hsp60 | Antibodies Against 60 kDa Heat Shock Protein |
| BDI-II | Beck Depression Inventory-II |
| BMI | Body Mass Index |
| BNP | B-Type Natriuretic Peptide |
| BRASS | Brigham and Women’s Rheumatoid Arthritis Sequential Study |
| C | Complement System |
| CAD | Coronary Artery Disease |
| CD | Cluster of Differentiation |
| CHD | Coronary Heart Disease |
| CIA | Collagen-Induced Arthritis |
| CMD | Coronary Microvascular Dysfunction |
| CRP | C-Reactive Protein |
| csDMARDs | Conventional Synthetic Disease-Modifying Antirheumatic Drugs |
| CV | Cardiovascular |
| CVD | Cardiovascular Disease |
| DAS28-CRP | Disease Activity Score 28 (or in 28 joints)-CRP |
| DBS | Dried Blood Spot |
| DMARDs | Disease-Modifying Anti-Rheumatic Drugs |
| EC | Endothelial Cell |
| ECG | Electrocardiogram |
| ELISA | Enzyme-Linked Immunosorbent Assay |
| ESR | Erythrocyte Sedimentation Rate |
| EV/EVs | Extracellular Vesicles |
| Fcγ receptors | Fc gamma receptors |
| FLS | Fibroblast-like Synoviocytes |
| HDL | High-Density Lipoprotein |
| hscTnT | High-Sensitivity Cardiac Troponin T |
| hsCRP | High-Sensitivity C-Reactive Protein |
| IFN-γ | Interferon-gamma |
| IL-1β | Interleukin-1 beta |
| IL-2 | Interleukin-2 |
| IL-6 | Interleukin-6 |
| IL-12 | Interleukin-12 |
| IL-18 | Interleukin-18 |
| IL-33 | Interleukin-33 |
| IMT | Intima-Media Thickness |
| JAKi | Janus Kinase Inhibitor |
| LDL-C | Low-Density Lipoprotein Cholesterol |
| LPS | Lipopolysaccharide |
| LpPLA2 | Lipoprotein-Associated Phospholipase A2 |
| MAPK | Mitogen-Activated Protein Kinase |
| MAC | Membrane Attack Complex |
| MACE | Major Adverse Cardiac Events |
| MCP-1 | Monocyte Chemoattractant Protein-1 |
| MDD | Major Depressive Disorder |
| MetS | Metabolic Syndrome |
| MFR | Myocardial Flow Reserve |
| MHC-II | Major Histocompatibility Complex Class II |
| MRI | Magnetic Resonance Imaging |
| MPs | Microparticles |
| mCRP | Monomeric C-Reactive Protein |
| MVs | Microvesicles |
| nCRP | Native (Pentameric) C-Reactive Protein |
| NK | Natural Killer Cells |
| NF-κB | Nuclear Factor Kappa-light-chain-enhancer of Activated B cells |
| NFTs | Neurofibrillary Tangles |
| NHIRD | National Health Insurance Research Database (Taiwan) |
| OA | Osteoarthritis |
| OPN | Osteopontin |
| PAD | Peripheral Artery Disease |
| PC | Phosphocholine |
| PE | Phosphoethanolamine |
| PET | Positron Emission Tomography |
| PHCs | Progenitor Hematopoietic Cells (CD34+ cells) |
| PHQ-9 | Patient Health Questionnaire-9 |
| pCRP/pCRP* | Pentameric C-Reactive Protein/Pentameric Symmetrical CRP (with neoepitope exposed)/Conformational Intermediate of CRP |
| PWV | Pulse Wave Velocity |
| RA | Rheumatoid Arthritis |
| RAGE/RAGEs | Receptor for Advanced Glycation End Products |
| RF | Rheumatoid Factor |
| ROS | Reactive Oxygen Species |
| sPLA2 | Secretory Phospholipase A2 |
| sRAGE | Soluble Receptor for Advanced Glycation End Products |
| SA | Stable Angina |
| S100A8/A9 | Calprotectin |
| SLE | Systemic Lupus Erythematosus |
| SSc | Systemic Sclerosis |
| SPs | Senile Plaques |
| ST2 | Suppression of Tumorigenicity 2 (soluble form often denoted as sST2) |
| STCS | Speckle Tracking Carotid Strain |
| suPAR | Soluble Urokinase Plasminogen Activator Receptor |
| TNF | Tumor Necrosis Factor |
| TNF-α | Tumor Necrosis Factor Alpha |
| TGF-β | Transforming Growth Factor Beta |
| VAS | Visual Analog Scale |
| VEGF | Vascular Endothelial Growth Factor |